The post Solana Breaks Below Head and Shoulders Pattern with $50 Target Ahead appeared on BitcoinEthereumNews.com. Key Insights: Solana falls below the macro HeadThe post Solana Breaks Below Head and Shoulders Pattern with $50 Target Ahead appeared on BitcoinEthereumNews.com. Key Insights: Solana falls below the macro Head

Solana Breaks Below Head and Shoulders Pattern with $50 Target Ahead

Key Insights:

  • Solana falls below the macro Head and Shoulders pattern, triggering bearish signals and a $50 price target.
  • Over 1.07 million SOL were withdrawn from exchanges in 72 hours, suggesting cautious investor behavior.
  • Solana DeFi TVL declines to $6.44 billion, showing reduced activity since peak in September 2025.
The Token Breaks Below Head and Shoulders Pattern with $50 Target Ahead

Solana (SOL)  price has dropped below a key technical pattern, raising concern across the market. The current trend is drawing attention from traders and analysts who are watching for lower price levels.

Breakdown from the Head and Shoulders Pattern

A widely followed chart pattern has been broken. This type of pattern is often seen as a sign of trend reversal. According to chart analyst Bitcoinsensus, Solana has confirmed a breakdown from this macro Head & Shoulders pattern, with a possible downside target near $50.

This pattern is used by traders to spot trend reversals. A move below its neckline often signals a shift from a rising to a falling market. This chart setup has been forming for months, and the recent decline has now activated its target.

As of the time of writing, Solana is trading at $85.72, down 1.45% in the past 24 hours. The decline follows growing technical pressure and market outflows that could push the price further down.

Decrease in Exchange Supply and ETF Outflows

Moreover In the last 72 hours, more than 1.07 million SOL have been withdrawn from exchanges. On-chain analyst Ali Charts noted this, hinting at growing uncertainty. It remains unclear whether these withdrawals are for self-custody or institutional holding.

At the same time, Solana-linked ETFs in the U.S. saw net outflows of $8.9 million last week. Based on SolanaFloor, a platform tracking the coin ecosystem metrics, most of this came from $BSOL, which accounted for $8.6 million. The ETF outflows often suggest lower institutional demand. While not always a sign of long-term weakness, they reflect short-term shifts in investor behavior. This trend may continue if overall sentiment stays weak.

TVL Drop Signals Lower DeFi Activity

Meanwhile, Solana’s total value locked (TVL) in DeFi protocols has fallen to $6.44 billion. This is a sharp drop from over $13 billion seen in late September 2025.

Solana Total Value Locked Drop | Source: DeFiLlama

The fall in TVL suggests less activity in lending, trading, and staking across Solana-based apps. This could be due to reduced liquidity, investor exits, or a reallocation of capital, as the decline has been more visible in early 2026.

As activity drops, user engagement across protocols has slowed. While some expect this trend to reverse, current data shows reduced growth in Solana’s DeFi sector.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.

Source: https://coincu.com/analysis/solana-breaks-below-head-and-shoulders/

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0005199
$0.0005199$0.0005199
+11.01%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26